923009-49-8 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule of the compound.
2. Derivative of piperidinedicarboxylic acid
Explanation
The compound is derived from piperidinedicarboxylic acid, which is a six-membered nitrogen-containing ring structure.
3. Building block in organic synthesis
Explanation
It is used as a starting material or intermediate in the synthesis of more complex organic compounds.
4. Pharmaceutical research and drug development
Explanation
The compound is utilized in the development of new drugs and pharmaceuticals due to its potential medicinal properties.
5. Medicinal properties
Explanation
The compound has properties that make it potentially useful in the treatment or prevention of diseases.
6. Chemical and physical properties
Explanation
The compound possesses a range of properties that make it suitable for various applications in the field of medicinal and pharmaceutical chemistry.
7. Importance in medicinal and pharmaceutical chemistry
Explanation
The compound plays a significant role in the development of new drugs and therapies, contributing to advancements in the field.
Check Digit Verification of cas no
The CAS Registry Mumber 923009-49-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,3,0,0 and 9 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 923009-49:
(8*9)+(7*2)+(6*3)+(5*0)+(4*0)+(3*9)+(2*4)+(1*9)=148
148 % 10 = 8
So 923009-49-8 is a valid CAS Registry Number.
923009-49-8Relevant articles and documents
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
, (2018/03/28)
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors
Yamashita, Tohru,Kamata, Makoto,Endo, Satoshi,Yamamoto, Mitsuo,Kakegawa, Keiko,Watanabe, Hiroyuki,Miwa, Katsuhiko,Yamano, Toru,Funata, Masaaki,Sakamoto, Jyun-Ichi,Tani, Akiyoshi,Mol, Clifford D.,Zou, Hua,Dougan, Douglas R.,Sang, BiChing,Snell, Gyorgy,Fukatsu, Kohji
scheme or table, p. 6314 - 6318 (2011/11/29)
The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly2162 and Glu2230, we used ligand- and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety
